Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
株式のランク #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
株価
$0.00244926
時価総額
$51.67K
変化(1日)
5.88%
変化(1年)
110.15%
GB
取引 Nuformix plc (NFX)

カテゴリー

Nuformix plc(NFX)の発行済株式数
September 2025 時点の発行済株式数 2.03B
Nuformix plc の最新の財務報告および株価によると、現在の発行済株式数は 2.03B です。September 2024 の終わりには、同社は 787.01M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Nuformix plc(NFX)の発行済株式数の履歴(2014 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
2026 (TTM) 2.03B 22.35%
2025 1.66B 111.05%
2024 787.01M 9.39%
2023 719.46M 20.22%
2022 598.45M 3.07%
2021 580.63M 21.71%
2020 477.06M 3.54%
2019 460.75M 23.34%
2018 373.55M 290.13%
2017 95.75M 59.34%
2016 60.09M 0.00%
2014 0.00 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数
4.45B 118.85%
DK
253.90M -87.51%
US
102.90M -94.94%
US
190.00M -90.65%
BE
483.58M -76.21%
AU